Axsome Therapeutics (19X) Price & Analysis

1 Followers

19X Stock Chart & Stats

€155.85

-€0.94(-1.16%)

At close: Jan 08 4:00 PM EST

€155.85

-€0.94(-1.16%)

Day’s Range― - ―

52-Week Range€85.70 - €226.30

Previous CloseN/A

Volume0.00

Average Volume (3M)38.00

Market Cap

€11.06B

Enterprise Value€12.89B

Total Cash (Recent Filing)€305.11M

Total Debt (Recent Filing)€219.90M

Price to Earnings (P/E)―

Beta0.61

Next Earnings

Aug 10, 2026

EPS Estimate

-0.75

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.73

Shares Outstanding51,459,766

10 Day Avg. Volume18

30 Day Avg. Volume38

Financial Highlights & Ratios

PEG Ratio1.29

Price to Book (P/B)102.90

Price to Sales (P/S)14.23

P/FCF Ratio-96.78

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€234.39

Price Target Upside50.39% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering16

EPS Forecast (FY)-1.87

Revenue Forecast (FY)€862.34M

Bulls Say, Bears Say

Bulls Say

Rapid Revenue Scale With High Gross MarginsSustained, rapid top-line growth combined with very high gross margins indicates durable product economics. High gross margins mean incremental sales flow through to cover fixed costs, enabling operating leverage as AUVELITY and SUNOSI scale and supporting long-term profitability once SG&A and R&D normalize.

AUVELITY First-in-class FDA ApprovalA first-in-class FDA approval in a high-unmet-need indication materially expands AUVELITY's addressable market and prescriber rationale. This durable regulatory foothold supports broader adoption, payer coverage, and the company's upgraded ~$8B peak sales thesis, strengthening long-term commercial upside.

SUNOSI Long-term U.S. Exclusivity SecuredResolving all SUNOSI patent litigation and locking a defined generic entry date through 2040 removes legal overhang and creates multi-year exclusivity. That clarity improves long-term revenue visibility from an established product and reduces the structural risk of near-term generic erosion.

Bears Say

Persistent Cash Burn And Negative FCFNegative operating and free cash flow indicate ongoing cash burn driven by commercialization and R&D. Even with improving trends, the company remains reliant on external funding or rapid margin improvement; this structural cash deficit constrains flexibility and risks dilution if growth or approvals slip.

Elevated Leverage And Thin Equity BaseHigh leverage relative to a small equity base reduces financial resilience. With significant debt outstanding while operations are cash-negative, refinancing and interest obligations heighten execution risk, making the company more vulnerable to adverse outcomes or delayed commercial milestones.

High Gross-to-net And Rising SG&AMaterial gross-to-net discounts materially reduce realized revenue despite strong list sales, and a sharp SG&A ramp to support launches raises the cash burn profile. Together these structural pressures compress margins, prolong break-even timing, and require sustained payer/access gains to realize the underlying economics.

Axsome Therapeutics News

Axsome Therapeutics price target raised to $304 from $302 at RBC Capital

RBC Capital analyst Leonid Timashev raised the firm’s price target on Axsome Therapeutics (AXSM) to $304 from $302...

3d ago

AXSM

Blair adds American Express, Oracle to Conviction List in monthly update

William Blair analysts, in their monthly update, added the following stocks to its Analyst Conviction List: American Express...

9d ago

Axsome Therapeutics doses first patient in FOCUS-3 trial

Axsome Therapeutics (AXSM) announced that the first patient has been dosed in the FOCUS-3 Phase 3 trial evaluating...

14d ago

AXSM

Axsome Therapeutics price target raised to $300 from $275 at TD Cowen

TD Cowen analyst Joseph Thome raised the firm’s price target on Axsome Therapeutics (AXSM) to $300 from $275...

23d ago

AXSM

Axsome Therapeutics: SUNOSI IP De-Risked, ADHD Phase 3 Expansion Supports Reaffirmed $290 12-Month Price Target and Buy Rating

Axsome Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...

2d ago

AXSM

Axsome Shareholders Back Directors, Auditor and Executive Pay

Axsome Therapeutics ( ($AXSM) ) has provided an update. At Axsome Therapeutics’ 2026 Annual Meeting of Stockholders held...

1M ago

AXSM

Axsome adopts new executive severance and control plan

Axsome Therapeutics ( ($AXSM) ) has shared an announcement. On June 5, 2026, Axsome Therapeutics’ board-level Compensation Committee...

1M ago

AXSM

Axsome Therapeutics: Buy Rating Reiterated, $290 Price Target Unchanged on Extended SUNOSI Exclusivity and Late-Stage Pipeline Progress

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Axsome Therapeutics today and set a price target...

1M ago

AXSM

Analyst Reaffirms Buy on Axsome as Auvelity Peak Sales Outlook Surges Above $8B and Cash Runway Extends to Breakeven

William Blair analyst Myles Minter has reiterated their bullish stance on AXSM stock, giving a Buy rating yesterday....

1M ago

AXSM

Axsome secures long-term U.S. exclusivity for SUNOSI

The latest announcement is out from Axsome Therapeutics ( ($AXSM) ). On June 3, 2026, Axsome Therapeutics announced...

1M ago

AXSM

Axsome Therapeutics announces settlement resolving Sunosi patent litigation

Axsome Therapeutics (AXSM) announced that it has resolved all patent litigation related to Axsome’s product Sunosi. The litigations...

1M ago

AXSM

Truist’s Suvannavejh Lifts Auvelity Outlook and Sets $310 Price Target on Axsome Therapeutics Buy Rating

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on AXSM stock, giving a Buy rating on...

2M ago

AXSM

Axsome Therapeutics price target lowered to $280 from $281 at Deutsche Bank

Deutsche Bank analyst David Hoang lowered the firm’s price target on Axsome Therapeutics (AXSM) to $280 from $281...

2M ago

AXSM

Axsome Therapeutics price target raised to $267 from $255 at Needham

Needham raised the firm’s price target on Axsome Therapeutics (AXSM) to $267 from $255 and keeps a Buy...

2M ago

AXSM

19X FAQ

What was Axsome Therapeutics Inc.’s price range in the past 12 months?

Axsome Therapeutics Inc. lowest stock price was €85.70 and its highest was €226.30 in the past 12 months.

What is Axsome Therapeutics Inc.’s market cap?

Axsome Therapeutics Inc.’s market cap is €11.06B.

When is Axsome Therapeutics Inc.’s upcoming earnings report date?

Axsome Therapeutics Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 31 days.

How were Axsome Therapeutics Inc.’s earnings last quarter?

Axsome Therapeutics Inc. released its earnings results on May 04, 2026. The company reported -€1.103 earnings per share for the quarter, missing the consensus estimate of -€0.739 by -€0.364.

Is Axsome Therapeutics Inc. overvalued?

According to Wall Street analysts Axsome Therapeutics Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Axsome Therapeutics Inc. pay dividends?

Axsome Therapeutics Inc. does not currently pay dividends.

What is Axsome Therapeutics Inc.’s EPS estimate?

Axsome Therapeutics Inc.’s EPS estimate is -0.75.

How many shares outstanding does Axsome Therapeutics Inc. have?

Axsome Therapeutics Inc. has 51,459,766 shares outstanding.

What happened to Axsome Therapeutics Inc.’s price movement after its last earnings report?

Axsome Therapeutics Inc. reported an EPS of -€1.103 in its last earnings report, missing expectations of -€0.739. Following the earnings report the stock price went up 10.459%.

Which hedge fund is a major shareholder of Axsome Therapeutics Inc.?

Currently, no hedge funds are holding shares in DE:19X

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Axsome Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-260.01%

Trailing 12-Months

Asset Growth

19.60%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Axsome Therapeutics Inc.

Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.

Axsome Therapeutics (19X) Earnings & Revenues

Historic Earnings Reports

19X Company Deck

19X Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveys strong commercial momentum and multiple material positive milestones: 57% YoY revenue growth, AUVELITY's new FDA approval and upgraded $8B peak-sales outlook, sales-force expansions, meaningful payer wins, and an advancing late-stage pipeline with recent BD adding AXS-20. Offsetting risks include materially higher SG&A, elevated gross-to-net discounts (notably for SYMBRAVO), a modest widening of net loss, a slight decline in cash, and remaining clinical/regulatory uncertainties for several pipeline assets. On balance, the positives (robust revenue growth, regulatory wins, and clear commercial execution) significantly outweigh the near-term financial and access headwinds.View all DE:19X earnings summaries

19X Stock 12 Month Forecast

Average Price Target

€234.39

▲(50.39% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"86":"€86","179":"€179","272":"€272","132.5":"€132.5","225.5":"€225.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":271.7955969,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€271.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":234.38717065999998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€234.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":175.351998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€175.35</span>\n  </div></div>","useHTML":true}}],"tickPositions":[86,132.5,179,225.5,272],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,213.3,217.79966130000003,222.2993226,226.79898390000002,231.2986452,235.79830650000002,240.2979678,244.79762910000002,249.2972904,253.79695170000002,258.29661300000004,262.7962743,267.2959356,{"y":271.7955969,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,213.3,214.92209005076924,216.54418010153847,218.1662701523077,219.78836020307693,221.41045025384616,223.0325403046154,224.6546303553846,226.27672040615383,227.89881045692306,229.5209005076923,231.14299055846152,232.76508060923075,{"y":234.38717065999998,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,213.3,210.38092292307692,207.46184584615386,204.54276876923078,201.62369169230772,198.70461461538463,195.78553753846154,192.86646046153848,189.9473833846154,187.02830630769233,184.10922923076924,181.19015215384616,178.2710750769231,{"y":175.351998,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":89.72,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.45,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.7,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.9,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.45,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":196.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":213.3,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >